Mat Robinson

Mat Robinson is VP Translational Biology for Microbiotica, responsible for understanding how the microbes interact with and impact the host, as well as the company’s immuno-oncology program.

Mat brings more than 20 years’ research experience across academic and industry. Mat previously led preclinical programs and teams in many disease areas in the Oncology and RIA (Respiratory, Inflammation, and Autoimmune) departments at MedImmune/AstraZeneca. This included strategic roles in inflammatory bowel disease and immuno-oncology. In addition, he was part of the clinical development teams for abrilumab, brakinumab and olcelumab, which delivered successful studies in ulcerative colitis, Crohn’s disease, and a number of oncology indications.

Mat holds a BSc in Biochemistry from the University of Bath and a Ph.D. in Immunology from the University College London. His postdoctoral research at Cancer Research UK and National Institute of Medical Research focused on how the sensing of microbes by the innate immune cells triggered inflammation and instructed the adaptive immune response.